MNG952
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.546
- E2F_TARGETS+0.495
- OXIDATIVE_PHOSPHORYLATION+0.443
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.387
- ANGIOGENESIS+0.364
- G2M_CHECKPOINT+0.359
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.349
- MYC_TARGETS_V1+0.345
- DNA_REPAIR+0.340
- MTORC1_SIGNALING+0.309
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.344
- TGF_BETA_SIGNALING-0.320
- UV_RESPONSE_DN-0.317
- INTERFERON_GAMMA_RESPONSE-0.294
- HEDGEHOG_SIGNALING-0.285
- HEME_METABOLISM-0.248
- PROTEIN_SECRETION-0.221
- ANDROGEN_RESPONSE-0.220
- WNT_BETA_CATENIN_SIGNALING-0.211
- TNFA_SIGNALING_VIA_NFKB-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-PQ-A6FN-01A-11R-A31N-07 | — | — | 0.841 |
| 2 | MDT-AP-2494 | Med | Medulloblastoma | 0.821 |
| 3 | TCGA-22-1012-01A-01R-0692-07 | — | cohortSQ2 | 0.810 |
| 4 | MNG158 | — | — | 0.804 |
| 5 | MNG1082 | — | — | 0.796 |
| 6 | TCGA-22-4607-01A-01R-1201-07 | — | cohortSQ1 | 0.786 |
| 7 | SRR6013603 | — | cohortA3 | 0.773 |
| 8 | MDT-AP-0203 | Med | Medulloblastoma | 0.772 |
| 9 | TCGA-EW-A1OZ-01A-11R-A144-07 | — | C | 0.760 |
| 10 | BS_R439VVPK | Med | Medulloblastoma | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.546 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.495 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.443 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.387 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.364 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.359 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.349 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.345 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.309 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.287 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.261 | Temsirolimus | — uncovered |
| COAGULATION | 0.256 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.224 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.217 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.189 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.184 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.175 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.172 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.167 | Idelalisib | — uncovered |